Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 is often described as a “double-edged sword” because of its ability both to suppress and activate the immune system. For cancer patients, increased levels of IL-2 correlate with improved survival. […]

Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and Duchenne Muscular Dystrophy. Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with delivery of genetic […]

Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases.  The company engages in the discovery and development of novel therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia, and Parkinson’s. These disorders impact memory, movement, language, behavior, and personality resulting in disability and death of millions of patients. […]

Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by several orders of magnitude. No technology currently exists that can sequence the amino acids of proteins at a single molecule level. To change this, Glyphic is developing a next generation […]

ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID’s aiSPIRE platform screens billions of antibody-target interactions while concurrently applying AI to reveal the history of immune responses in each patient. ImmuneID combines this proprietary data with deep patient-specific clinical findings and private and public […]

Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation and mutations.  Transcription factors (TFs) have long been the aspirational targets of drug developers, based on their central role in cancer and other diseases. TFs are DNA-binding proteins that can […]

Shoreline Biosciences is developing genetically engineered induced pluripotent stem cell (iPSC)-derived allogeneic natural killer (NK) and macrophage cellular immunotherapies that are intelligently designed for greater potency and persistence, to create safe, effective, and affordable immunotherapies for the treatment of seriously ill patients. Shoreline’s proprietary cell therapy platform is based on deep expertise in iPSC differentiation […]

Exo Therapeutics leverages its ExoSite™ platform to develop a deep pipeline of potent drug candidates that bind exosites – distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Enzymes play key roles in all metabolic processes, such as destroying toxins and aiding digestion. This critical […]

Garuda Therapeutics develops off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases. Garuda’s platform for generating off-the-shelf, self-renewing blood stem cells is designed to provide patients with rapid and broad access to consistent, durable, HLA-matched, transgene-free blood stem cell therapies. Currently, patients seeking a blood stem cell transplant, […]

PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring health and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation. PAQ uses its ATTEC (autophagosome-tethering compound) technology, where small molecules can selectively enhance the degradation of disease causing entities. PAQ’s research advances are driving an important new class […]

Congruence Therapeutics is working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. Congruence is building its own proprietary AI engine, Revenir, using publicly available and unique datasets by incorporating computational biophysics to tackle the protein misfolding problem in rare diseases. This purpose-built technology uses […]

Perturba Therapeutics a oncology focused spin out from the University of Toronto advancing a pipeline of assets from undrugged protein-protein interactions (PPIs). Founded in 2021 as a venture between AI drug discovery company Cyclica and the Stagljar Lab at the University of Toronto, Perturba integrates Cyclica’s AI-augmented drug discovery platform with sensitive live cell-based technologies […]

Alethiomics is an Oxford University spin-out applying innovations in single-cell multi-omic analysis to the development of novel therapeutics for myeloproliferative neoplasms (MPNs). MPNs are a group of chronic blood cancers that begin with mutations occurring in cancer stem cells in the bone marrow. While currently available treatments can relieve symptoms, they do not tackle the […]

Eradivir has developed a small molecule technology that tethers immune cells to diseased cells, with the potential to treat multiple viral diseases and cancers. Eradivir “MiniBITs” are small bispecific molecules that engage both a cytotoxic immune cell and a virus/virus-infected or cancer cell. Upon bridging between the two cell types, the immune cell is activated […]

Protai has built an AI-based platform that maps the course of diseases on the protein level, enhancing the ability to observe cellular function and discover new drugs. By systematically mapping diseases on the protein level the company aims to create an entirely new layer of functional information that enables identification of therapeutic and diagnostic targets. […]

NonExomics is focused on the non-exome regions of the genome and has identified hundreds of potential new drug targets across rare diseases, neuropsychiatric disorders, and cancer. The parts of our DNA that code for proteins make up around 2% of the human genome and are collectively known as the exome. The exome is the best […]

Amyl Therapeutics is Belgian preclinical biotech company developing a technology platform to bind various types of amyloid fibrils and induce their clearance, potentially offering a breakthrough approach to treating protein misfolding diseases. Amyloidosis is a group of diseases characterized by an endogenous production of misfolded proteins that aggregate as insoluble amyloid fibrils and form deposits […]

Resalis Therapeutics is a biopharma company focused on the development of antisense oligonucleotide (ASO) therapies to treat metabolic disorders, including MAFLD/NAFLD/NASH, obesity, and cancer. Resalis is applying LNA (locked nucleic acid) technology to inhibit miR-22 activity and restore a healthy homeostat in livers affected by metabolic disorders. miR-22 is a key player in the regulation […]

Comanche Biopharma is developing novel siRNA (Small interfering RNA) compounds to treat preeclampsia via gene silencing. The protein sFLT-1 is believed to be the cause of preeclampsia. This protein, produced by the placenta and measurable in the plasma of pregnant women, is both diagnostic and prognostic for preeclampsia and is causally responsible for its disease […]

NextRNA Therapeutics was founded in 2020 to pursue non-coding RNAs as a new class of therapeutic target for diseases including cancer, infectious diseases, and autoimmune disorders. There are many RNAs that do not make proteins, called non-coding RNAs (ncRNA). These ncRNAs are able to regulate essential processes and when altered cause disease. NextRNA has developed […]